Predictions that the Supreme Court decision would lead to lower prices and increased access to BRCA genetic testing in the US appear to have been correct; although Myriad clearly wishes to remain the sole provider, the mere threat of compulsory licensing appears to have stimulated a widening of access.
Now the chair of the US Senate Judiciary Committee has reportedly asked National Institutes of Health (NIH) Director Francis Collins to use a legal provision to compel Myriad Genomics to offer licenses for BRCA testing on reasonable terms.
Share this article
Read the full article here: Could Myriad be forced to license BRCA testing in US?
